Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients

<div>Kaplan–Meier curves of progression-free survival and overall survival from the introduction of first-line treatment for metastatic cervical cancer; TCB = bevacizumab in combination with cisplatin and paclitaxel backbone chemotherapy; CHT = chemotherapy.</div>

Journal of Oncology

fig1

Figure 1

Figure 1: Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients 

Figure 1 | Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients 